- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This is the definitive source for medical management of ulcerative colitis. It provides gastroenterologists and those in training with the necessary information to successfully manage the patient with ulcerative colitis.
Andere Kunden interessierten sich auch für
- Medical Therapy of Ulcerative Colitis111,99 €
- Devinder KumarCrohn¿s Disease and Ulcerative Colitis37,99 €
- Medical Therapy of Ulcerative Colitis75,99 €
- Melissa G HuntCoping with Crohn's and Colitis148,99 €
- A Clinical Guide to Colitis150,99 €
- Colitis and Crohn's: Understanding and Managing Inflammatory Bowel Disease139,99 €
- Ulcerative Colitis, an Issue of Gastroenterology Clinics of North America115,99 €
-
-
-
This is the definitive source for medical management of ulcerative colitis. It provides gastroenterologists and those in training with the necessary information to successfully manage the patient with ulcerative colitis.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis Ltd (Sales)
- Seitenzahl: 502
- Erscheinungstermin: 15. Mai 2011
- Englisch
- Abmessung: 307mm x 221mm x 30mm
- Gewicht: 1919g
- ISBN-13: 9781556429453
- ISBN-10: 1556429452
- Artikelnr.: 29251321
- Verlag: Taylor & Francis Ltd (Sales)
- Seitenzahl: 502
- Erscheinungstermin: 15. Mai 2011
- Englisch
- Abmessung: 307mm x 221mm x 30mm
- Gewicht: 1919g
- ISBN-13: 9781556429453
- ISBN-10: 1556429452
- Artikelnr.: 29251321
Gary R. Lichtenstein, MD,FACP, FACG, AGAF is the Director of the Inflammatory Bowel Disease Center and a Professor of Medicine in the Gastrointestinal Division of the Department of Medicine at the Hospital of the University of Pennsylvania and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. Dr. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine in New York, New York. He then completed his internship and residency in Internal Medicine at Duke University Medical Center in Durham, North Carolina. He also served a fellowship in Gastroenterology at the Hospital of the University of Pennsylvania of the University Of Pennsylvania School of Medicine. His current research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn's disease. Dr. Lichtenstein has received numerous research grants focusing on these areas and has served as the national/international principal investigator evaluating novel agents for therapeutic trials in the treatment of ulcerative colitis and Crohn's disease. A Fellow of the American Gastroenterological Association, the American College of Physicians, and the American College of Gastroenterology, Dr. Lichtenstein has served as Medical Secretary for the American Board of Internal Medicine, Gastroenterology Section. He holds membership and committee positions in many professional societies at a national level, including the American Gastroenterological Association, where he has served as the vice-chair of the Clinical Practice Committee and Practice Economics Committee and where he has served as chair of the Clinical Practice Committee; the American Society for Gastrointestinal Endoscopy, where he has served on the Committee on Training; and the American College of Gastroenterology, where he has served on the Education Committee, Programs Committee, and the Nominations Committee. He recently served as a member of the Research Committee. He has been the chair of the Abstract Review Committee for Inflammatory Bowel Disease for the American College of Gastroenterology. He is also a member of the Crohn's and Colitis Foundation of America, where he serves at the national level as the chair of the Membership Committee of the Clinical Research Alliance; he has served on the National Grants Review Committee and the National Physician Education Committee as well. Additionally, Dr. Lichtenstein is a longstanding member of the American College of Physicians and the American Medical Association. Dr. Lichtenstein has received numerous awards. including the award for the top specialist in the University of Pennsylvania Health System-the Louis A. Duhring Award. He is the recipient of the Christina and Marie Lindback award, which is the top teaching award in the entire University of Pennsylvania. He has received Penn Pearls Award for medical school teaching. He has received the Donald B. Martin Teaching Award for the Department of Medicine Housestaff. He has received the Sidney Cohen Teaching Award for the Gastroenterology Division. He is listed in "The Best Doctors in America" for Inflammatory Bowel Disease, and was listed among the Top Gastroenterologists for the Elderly in Philadelphia and Top Gastroenterologists in Philadelphia (Special Focus: Inflammatory Bowel Disease) by Philadelphia Magazine. He is the recipient of the CCFA Physician of the Year Award, Philadelphia and Delaware Valley Chapters. In addition to having served on the Editorial Board of Gastroenterology, American Journal of Gastroenterology, Inflammatory Bowel Diseases, World Journal of Gastroenterology,and Digestive Diseases and Sciences, Dr. Lichtenstein is the current section editor of Selected Summaries and the section editor of Print and Media Review in Gastroenterology. He has served as a reviewer for such journals as The New England Journal of Medicine, Gastroenterology, The Lancet, the Annals of Internal Medicine, Gut, Journal of Parenteral and Enteral Nutrition, the American Journal of Gastroenterology, the World Journal of Gastroenterology and the Journal of Clinical Gastroenterology. He is the executive editor of the newly indexed journal Gastroenterology and Hepatology, and serves as Associate Editor of Therapeutic Advances in Gastroenterology, The Physician and Sportsmedicine, and Clinical Investigation, and is currently Assistant Editor-in-Chief of the World Journal of Gastroenterology. An invited lecturer at the local, national, and international levels, Dr. Lichtenstein is the author or co-author of more than 250 peer-reviewed primary articles, chapters, letters, and editorials, and he has presented over 250 abstracts and edited 18 books. He has lectured at over 300 invited conferences, symposiums, and institutional grand rounds. Ellen J. Scherl, MD, FACP, AGAF, is the Jill Roberts Associate Professor of Clinical Medicine and Director of The Jill Roberts Center for Inflammatory Bowel Disease at Weill Medical College of Cornell University/New York-Presbyterian Hospital. She holds a bachelor's degree in English from Barnard College, Columbia University, and a medical degree from New York Medical College. She is a fellow of the American College of Physicians and the American Gastroenterological Association (AGA), a member of the American Society of Gastrointestinal Endoscopy, and a past president of the New York Society for Gastrointestinal Endoscopy (NYSGE). She is currently Vice President of the New York Academy of Gastroenterology. Dr. Scherl is Chairperson of the New York Chapter of the Crohn's and Colitis Foundation of America and is involved in the New York Crohn's Foundation. She received the 2008 AGA Outstanding Women in Science award and the 2006 NYSGE Florence Lefcourt Distinguished Service Award, and has been awarded by the Crohn's and Colitis Foundation of America. She is an American Society of Gastrointestinal Endoscopy Circle of Life Member and a member of the AGA Legacy Society. She is board certified in medicine and gastroenterology. Dr. Scherl is an editorial reviewer for IBD Journal, Journal of Clinical Gastroenterology, Gastrointestinal Endoscopy, Digestive Diseases and Sciences, and Journal of Gastroenterology and Hepatology. She is co-author of the chapter "Crohn's Disease of the Small Intestine" in Gastroenterology and Hepatology: The Comprehensive Visual Reference, associate editor of Inflammatory Bowel Disease: The Complete Guide to Medical Management, and coauthor of An Interactive Dialogue on IBD. Dr. Scherl established the first IBD tissue bank in New York City at Weill Medical College of Cornell University/New York-Presbyterian Hospital. She has extensive experience as an investigator in clinical trials and is currently participating in national multicenter trials and in investigator-initiated trials focusing on ulcerative colitis and Crohn's disease.
Dedication Acknowledgments About the Editor and Associate Editor Contributing Authors Introduction Prologue Historical Perspective of Ulcerative Colitis Ming V. Lin
MD; Wojciech Blonski
MD
PhD; David Kotlyar
MD; and Gary R. Lichtenstein
MD
FACP
FACG
AGAF Section I General Chapter 1 The Natural History of Inflammatory Bowel Disease Pietro G. Andres
MD and Lawrence S. Friedman
MD Chapter 2 Clinical Research in Inflammatory Bowel Disease: Placebo Response in Clinical Trials Chinyu Su
MD and James D. Lewis
MD
MSCE Chapter 3 The Role of the FDA in Drug Development in Inflammatory Bowel Disease Alan C. Moss
MD
FACG and Adam S. Cheifetz
MD Chapter 4 Utility of Animal Models for the Study and Treatment of Inflammatory Bowel Disease Ashish Chawla
MD and Kenneth Simpson
BVM&S
PhD Chapter 5 Pediatric Considerations in Medical Therapy in Patients With Inflammatory Bowel Disease Louis R. Ghanem
MD
PhD and Robert N. Baldassano
MD Chapter 6 The Limitations of Applying Evidence-Based Medicine to Inflammatory Bowel Disease: What We Do Not Learn From Clinical Trials Joshua R. Korzenik
MD and Corey A. Siegel
MD Chapter 7 Disease Modifiers in Inflammatory Bowel Disease Jaime A. Oviedo
MD and Francis A. Farraye
MD
MSc
FACP
FACG Chapter 8 Fertility and Pregnancy in Inflammatory Bowel Disease Jeffry A. Katz
MD and Vinita Elizabeth Jacob
MD Chapter 9 Diversion Colitis Eugeni Dom\u00e8nech
MD
PhD and Miguel A. Gassull
MD
PhD Chapter 10 Medication Adherence in Inflammatory Bowel Disease Sunanda V. Kane
MD
MSPH
FACG
FACP
AGAF Section II Medications Chapter 11 General Principles of Medical Therapy of Ulcerative Colitis Sonia Friedman
MD
FACP Chapter 12 Assessment of Disease Activity in Ulcerative Colitis Anthony L. Rosa
MD and Thomas A. Judge
MD Chapter 13 Current and Future Oral Mesalamine Derivative Use in Ulcerative Colitis Lloyd Sutherland
MDCM
MSc
FRCP(C)
FACP Chapter 14 Current and Future Topical Mesalamine Derivatives in Ulcerative Colitis Jeffrey W. Nathanson
MD and Russell D. Cohen
MD Chapter 15 Antibiotics in Ulcerative Colitis Kim L. Isaacs
MD
PhD Chapter 16 Oral and Parenteral Corticosteroids in Ulcerative Colitis Leonard Baidoo
MD and Gary R. Lichtenstein
MD
FACP
FACG
AGAF Chapter 17 Topical Corticosteroid Use in Ulcerative Colitis Seymour Katz
MD
FACP
MACG Chapter 18 6-Mercaptopurine and Azathioprine Use in Ulcerative Colitis Marla C. Dubinsky
MD Chapter 19 Azathioprine Metabolism in Inflammatory Bowel Disease: A PhysicianÆs Guide to Metabolite Testing Carmen Cuffari
MD Chapter 20 Methotrexate in the Treatment of Ulcerative Colitis Ellen J. Scherl
MD
FACP
AGAF; Vinita Elizabeth Jacob
MD; Brian P. Bosworth
MD; Ryan Urquhart Warren
MD; and Harrison Lakehomer
BA Chapter 21 Calcineurin Inhibitors (Cyclosporine
Tacrolimus
Sirolimus) and Mycophenolate Motefil Use in Ulcerative Colitis Hans Herfarth
MD
PhD and J\u00fcrgen Sch\u00f6lmerich
MD
PhD Chapter 22 Infliximab Use in Ulcerative Colitis Wojciech Blonski
MD
PhD; Antoni Stadnicki
MD
PhD; Gary R. Lichtenstein
MD
FACP
FACG
AGAF;
MD; Wojciech Blonski
MD
PhD; David Kotlyar
MD; and Gary R. Lichtenstein
MD
FACP
FACG
AGAF Section I General Chapter 1 The Natural History of Inflammatory Bowel Disease Pietro G. Andres
MD and Lawrence S. Friedman
MD Chapter 2 Clinical Research in Inflammatory Bowel Disease: Placebo Response in Clinical Trials Chinyu Su
MD and James D. Lewis
MD
MSCE Chapter 3 The Role of the FDA in Drug Development in Inflammatory Bowel Disease Alan C. Moss
MD
FACG and Adam S. Cheifetz
MD Chapter 4 Utility of Animal Models for the Study and Treatment of Inflammatory Bowel Disease Ashish Chawla
MD and Kenneth Simpson
BVM&S
PhD Chapter 5 Pediatric Considerations in Medical Therapy in Patients With Inflammatory Bowel Disease Louis R. Ghanem
MD
PhD and Robert N. Baldassano
MD Chapter 6 The Limitations of Applying Evidence-Based Medicine to Inflammatory Bowel Disease: What We Do Not Learn From Clinical Trials Joshua R. Korzenik
MD and Corey A. Siegel
MD Chapter 7 Disease Modifiers in Inflammatory Bowel Disease Jaime A. Oviedo
MD and Francis A. Farraye
MD
MSc
FACP
FACG Chapter 8 Fertility and Pregnancy in Inflammatory Bowel Disease Jeffry A. Katz
MD and Vinita Elizabeth Jacob
MD Chapter 9 Diversion Colitis Eugeni Dom\u00e8nech
MD
PhD and Miguel A. Gassull
MD
PhD Chapter 10 Medication Adherence in Inflammatory Bowel Disease Sunanda V. Kane
MD
MSPH
FACG
FACP
AGAF Section II Medications Chapter 11 General Principles of Medical Therapy of Ulcerative Colitis Sonia Friedman
MD
FACP Chapter 12 Assessment of Disease Activity in Ulcerative Colitis Anthony L. Rosa
MD and Thomas A. Judge
MD Chapter 13 Current and Future Oral Mesalamine Derivative Use in Ulcerative Colitis Lloyd Sutherland
MDCM
MSc
FRCP(C)
FACP Chapter 14 Current and Future Topical Mesalamine Derivatives in Ulcerative Colitis Jeffrey W. Nathanson
MD and Russell D. Cohen
MD Chapter 15 Antibiotics in Ulcerative Colitis Kim L. Isaacs
MD
PhD Chapter 16 Oral and Parenteral Corticosteroids in Ulcerative Colitis Leonard Baidoo
MD and Gary R. Lichtenstein
MD
FACP
FACG
AGAF Chapter 17 Topical Corticosteroid Use in Ulcerative Colitis Seymour Katz
MD
FACP
MACG Chapter 18 6-Mercaptopurine and Azathioprine Use in Ulcerative Colitis Marla C. Dubinsky
MD Chapter 19 Azathioprine Metabolism in Inflammatory Bowel Disease: A PhysicianÆs Guide to Metabolite Testing Carmen Cuffari
MD Chapter 20 Methotrexate in the Treatment of Ulcerative Colitis Ellen J. Scherl
MD
FACP
AGAF; Vinita Elizabeth Jacob
MD; Brian P. Bosworth
MD; Ryan Urquhart Warren
MD; and Harrison Lakehomer
BA Chapter 21 Calcineurin Inhibitors (Cyclosporine
Tacrolimus
Sirolimus) and Mycophenolate Motefil Use in Ulcerative Colitis Hans Herfarth
MD
PhD and J\u00fcrgen Sch\u00f6lmerich
MD
PhD Chapter 22 Infliximab Use in Ulcerative Colitis Wojciech Blonski
MD
PhD; Antoni Stadnicki
MD
PhD; Gary R. Lichtenstein
MD
FACP
FACG
AGAF;
Dedication Acknowledgments About the Editor and Associate Editor Contributing Authors Introduction Prologue Historical Perspective of Ulcerative Colitis Ming V. Lin
MD; Wojciech Blonski
MD
PhD; David Kotlyar
MD; and Gary R. Lichtenstein
MD
FACP
FACG
AGAF Section I General Chapter 1 The Natural History of Inflammatory Bowel Disease Pietro G. Andres
MD and Lawrence S. Friedman
MD Chapter 2 Clinical Research in Inflammatory Bowel Disease: Placebo Response in Clinical Trials Chinyu Su
MD and James D. Lewis
MD
MSCE Chapter 3 The Role of the FDA in Drug Development in Inflammatory Bowel Disease Alan C. Moss
MD
FACG and Adam S. Cheifetz
MD Chapter 4 Utility of Animal Models for the Study and Treatment of Inflammatory Bowel Disease Ashish Chawla
MD and Kenneth Simpson
BVM&S
PhD Chapter 5 Pediatric Considerations in Medical Therapy in Patients With Inflammatory Bowel Disease Louis R. Ghanem
MD
PhD and Robert N. Baldassano
MD Chapter 6 The Limitations of Applying Evidence-Based Medicine to Inflammatory Bowel Disease: What We Do Not Learn From Clinical Trials Joshua R. Korzenik
MD and Corey A. Siegel
MD Chapter 7 Disease Modifiers in Inflammatory Bowel Disease Jaime A. Oviedo
MD and Francis A. Farraye
MD
MSc
FACP
FACG Chapter 8 Fertility and Pregnancy in Inflammatory Bowel Disease Jeffry A. Katz
MD and Vinita Elizabeth Jacob
MD Chapter 9 Diversion Colitis Eugeni Dom\u00e8nech
MD
PhD and Miguel A. Gassull
MD
PhD Chapter 10 Medication Adherence in Inflammatory Bowel Disease Sunanda V. Kane
MD
MSPH
FACG
FACP
AGAF Section II Medications Chapter 11 General Principles of Medical Therapy of Ulcerative Colitis Sonia Friedman
MD
FACP Chapter 12 Assessment of Disease Activity in Ulcerative Colitis Anthony L. Rosa
MD and Thomas A. Judge
MD Chapter 13 Current and Future Oral Mesalamine Derivative Use in Ulcerative Colitis Lloyd Sutherland
MDCM
MSc
FRCP(C)
FACP Chapter 14 Current and Future Topical Mesalamine Derivatives in Ulcerative Colitis Jeffrey W. Nathanson
MD and Russell D. Cohen
MD Chapter 15 Antibiotics in Ulcerative Colitis Kim L. Isaacs
MD
PhD Chapter 16 Oral and Parenteral Corticosteroids in Ulcerative Colitis Leonard Baidoo
MD and Gary R. Lichtenstein
MD
FACP
FACG
AGAF Chapter 17 Topical Corticosteroid Use in Ulcerative Colitis Seymour Katz
MD
FACP
MACG Chapter 18 6-Mercaptopurine and Azathioprine Use in Ulcerative Colitis Marla C. Dubinsky
MD Chapter 19 Azathioprine Metabolism in Inflammatory Bowel Disease: A PhysicianÆs Guide to Metabolite Testing Carmen Cuffari
MD Chapter 20 Methotrexate in the Treatment of Ulcerative Colitis Ellen J. Scherl
MD
FACP
AGAF; Vinita Elizabeth Jacob
MD; Brian P. Bosworth
MD; Ryan Urquhart Warren
MD; and Harrison Lakehomer
BA Chapter 21 Calcineurin Inhibitors (Cyclosporine
Tacrolimus
Sirolimus) and Mycophenolate Motefil Use in Ulcerative Colitis Hans Herfarth
MD
PhD and J\u00fcrgen Sch\u00f6lmerich
MD
PhD Chapter 22 Infliximab Use in Ulcerative Colitis Wojciech Blonski
MD
PhD; Antoni Stadnicki
MD
PhD; Gary R. Lichtenstein
MD
FACP
FACG
AGAF;
MD; Wojciech Blonski
MD
PhD; David Kotlyar
MD; and Gary R. Lichtenstein
MD
FACP
FACG
AGAF Section I General Chapter 1 The Natural History of Inflammatory Bowel Disease Pietro G. Andres
MD and Lawrence S. Friedman
MD Chapter 2 Clinical Research in Inflammatory Bowel Disease: Placebo Response in Clinical Trials Chinyu Su
MD and James D. Lewis
MD
MSCE Chapter 3 The Role of the FDA in Drug Development in Inflammatory Bowel Disease Alan C. Moss
MD
FACG and Adam S. Cheifetz
MD Chapter 4 Utility of Animal Models for the Study and Treatment of Inflammatory Bowel Disease Ashish Chawla
MD and Kenneth Simpson
BVM&S
PhD Chapter 5 Pediatric Considerations in Medical Therapy in Patients With Inflammatory Bowel Disease Louis R. Ghanem
MD
PhD and Robert N. Baldassano
MD Chapter 6 The Limitations of Applying Evidence-Based Medicine to Inflammatory Bowel Disease: What We Do Not Learn From Clinical Trials Joshua R. Korzenik
MD and Corey A. Siegel
MD Chapter 7 Disease Modifiers in Inflammatory Bowel Disease Jaime A. Oviedo
MD and Francis A. Farraye
MD
MSc
FACP
FACG Chapter 8 Fertility and Pregnancy in Inflammatory Bowel Disease Jeffry A. Katz
MD and Vinita Elizabeth Jacob
MD Chapter 9 Diversion Colitis Eugeni Dom\u00e8nech
MD
PhD and Miguel A. Gassull
MD
PhD Chapter 10 Medication Adherence in Inflammatory Bowel Disease Sunanda V. Kane
MD
MSPH
FACG
FACP
AGAF Section II Medications Chapter 11 General Principles of Medical Therapy of Ulcerative Colitis Sonia Friedman
MD
FACP Chapter 12 Assessment of Disease Activity in Ulcerative Colitis Anthony L. Rosa
MD and Thomas A. Judge
MD Chapter 13 Current and Future Oral Mesalamine Derivative Use in Ulcerative Colitis Lloyd Sutherland
MDCM
MSc
FRCP(C)
FACP Chapter 14 Current and Future Topical Mesalamine Derivatives in Ulcerative Colitis Jeffrey W. Nathanson
MD and Russell D. Cohen
MD Chapter 15 Antibiotics in Ulcerative Colitis Kim L. Isaacs
MD
PhD Chapter 16 Oral and Parenteral Corticosteroids in Ulcerative Colitis Leonard Baidoo
MD and Gary R. Lichtenstein
MD
FACP
FACG
AGAF Chapter 17 Topical Corticosteroid Use in Ulcerative Colitis Seymour Katz
MD
FACP
MACG Chapter 18 6-Mercaptopurine and Azathioprine Use in Ulcerative Colitis Marla C. Dubinsky
MD Chapter 19 Azathioprine Metabolism in Inflammatory Bowel Disease: A PhysicianÆs Guide to Metabolite Testing Carmen Cuffari
MD Chapter 20 Methotrexate in the Treatment of Ulcerative Colitis Ellen J. Scherl
MD
FACP
AGAF; Vinita Elizabeth Jacob
MD; Brian P. Bosworth
MD; Ryan Urquhart Warren
MD; and Harrison Lakehomer
BA Chapter 21 Calcineurin Inhibitors (Cyclosporine
Tacrolimus
Sirolimus) and Mycophenolate Motefil Use in Ulcerative Colitis Hans Herfarth
MD
PhD and J\u00fcrgen Sch\u00f6lmerich
MD
PhD Chapter 22 Infliximab Use in Ulcerative Colitis Wojciech Blonski
MD
PhD; Antoni Stadnicki
MD
PhD; Gary R. Lichtenstein
MD
FACP
FACG
AGAF;